Newsroom | 35901 results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-fatal complication of stem-cell transplantation driven by activation of the lectin pathway of complement. YARTEMLEA is the first and only approved lectin pathway inhibitor. YARTEMLEA selectively inhibits MASP-2, the ef...

NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (OTCQB: QTIH) (“QT Imaging” or the “Company”), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today confirms that it finalized the shipment of 40 scanners and met its revenue guidance of more than $18 million in 2025. “2025 was a transitional year for QT Imaging as we moved from early commercialization to scaled execution. We met our objectives and shipped scanners in...

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced the appointment of Jeffrey R. Williams as Independent Director. “We are pleased to welcome Jeffrey to our Board of Directors for PharmaEssentia USA,” said Ko-Chung Lin, Ph.D., Founder and Chief Execu...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare’s polymerase theta (Polθ) ATPase inhibitor, RP-3467 (the “Gilead Agreement”). “We are pleased to announce this transaction which combines Gilead’s leading expertise in oncology research and development with RP-3467, a potential best-in-class...

SAN DIEGO--(BUSINESS WIRE)--Janux provided a program update on its Phase 1 study of JANX008, an EGFR-targeted TRACTr, following Phase 1a completion and cohort expansion....

PLANTATION, Fla.--(BUSINESS WIRE)--Akumin Inc. (together with its subsidiaries “Akumin” or the “Company”) announced today that it entered into an agreement (the “Support Agreement”) with certain noteholders representing over 95% of outstanding senior secured notes due in 2027 and 2028 (together, the “Senior Secured Notes”), and Stonepeak, a leading alternative investment firm, that will reduce debt, enhance liquidity and extend its debt maturities related to the Senior Secured Notes. Under the...

ROCHESTER, Minn.--(BUSINESS WIRE)--Vyriad announced $25M final tranche of its Series B to support the first-in-human testing of VV169, Vyriad’s in vivo CAR-T candidate....

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating botensilimab plus balstilimab (BOT+BAL) in The Journal for ImmunoTherapy of Cancer (JITC). The peer-reviewed manuscript titled, “Botensilimab (Fc-enhanced anti–CTLA-4 antibody) plus balstilimab (anti–PD-1 antibody) in patients with treatment-refractory ovarian cancer,” i...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2026 before the market open on Tuesday, January 6, 2026. The Company’s management will host a conference call at 8:00 am ET the same day to...

東京--(BUSINESS WIRE)--（ビジネスワイヤ） -- インサイト・バイオサイエンシズ・ジャパン合同会社（Incyte Biosciences Japan G.K.）は、再発・難治性濾胞性リンパ腫（FL）のうち、2次治療以降（2L+）の成人患者を対象とした、リツキシマブとレナリドミドとの併用療法である「ミンジュビ®（タファシタマブ）」について、厚生労働省（MHLW）より承認を取得したことを発表しました。 「リツキシマブおよびレナリドミドとの併用によるミンジュビの承認は、日本における再発・難治性FLを対象とした、CD19とCD20を同時に標的とする免疫療法併用として初の承認であり、重要な節目となります」と、インサイト・バイオサイエンシズ・ジャパンのジェネラルマネジャーである石田靖之は述べています。「無増悪生存期間の改善により、ミンジュビは、再発・難治性疾患の適格患者に対して、化学療法を用いない治療選択肢を提供します。今回の承認は、日本において、この困難な疾患の影響を受ける患者とそのご家族にとって重要な治療上のギャップを埋めるという、当社の取り組みを明確に示すものです。」 本...